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Background: Chemical imaging of the human brain has great potential for diagnostic and monitoring purposes.
The heterogeneity of human brain iron distribution, and alterations to this distribution in Alzheimer’s disease,
indicate iron as a potential endogenous marker. The inﬂuence of iron on certain magnetic resonance imaging
(MRI) parameters increases with magnetic ﬁeld, but is under-explored in human brain tissues above 7 T.
New Method: Magnetic resonance microscopy at 9.4 T is used to calculate parametric images of chemically-
unﬁxed post-mortem tissue from Alzheimer’s cases (n=3) and healthy controls (n= 2). Iron-rich regions in-
cluding caudate nucleus, putamen, globus pallidus and substantia nigra are analysed prior to imaging of total
iron distribution with synchrotron X-ray ﬂuorescence mapping. Iron ﬂuorescence calibration is achieved with
adjacent tissue blocks, analysed by inductively coupled plasma mass spectrometry or graphite furnace atomic
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absorption spectroscopy.
Results: Correlated MR images and ﬂuorescence maps indicate linear dependence of R2, R2* and R2’ on iron at
9.4 T, for both disease and control, as follows: [R2(s−1)= 0.072[Fe] + 20]; [R2*(s−1)= 0.34[Fe] + 37];
[R2’(s−1)= 0.26[Fe] + 16] for Fe in μg/g tissue (wet weight).
Comparison with Existing Methods: This method permits simultaneous non-destructive imaging of most bioa-
vailable elements. Iron is the focus of the present study as it oﬀers strong scope for clinical evaluation; the
approach may be used more widely to evaluate the impact of chemical elements on clinical imaging parameters.
Conclusion: The results at 9.4 T are in excellent quantitative agreement with predictions from experiments
performed at lower magnetic ﬁelds.
1. Introduction
1.1. The need for biomarkers of Alzheimer’s disease
Despite recent improvement in the proportion of individuals with
dementia receiving a diagnosis, conﬁrmation of a diagnosis of
Alzheimer’s disease is generally dependent on post mortem examination
of the underlying disease pathology. Developments in imaging, in-
cluding PET (positron emission tomography) imaging of amyloid de-
position, volumetric MRI (magnetic resonance imaging) of brain
atrophy and measurement of amyloid in the cerebral spinal ﬂuid (CSF)
have led to a series of proposals and recommendations to update AD
diagnostic criteria e.g. (Dubois et al., 2010; McKhann et al., 2011;
Dubois et al., 2016; Morris et al., 2014; Jack et al., 2013). The identi-
ﬁcation and monitoring of markers, and characterising marker proﬁles
as a function of disease progression, remain major challenges in Alz-
heimer’s research.
MRI is a particularly attractive diagnostic tool as it is non-invasive
and does not require exposure to ionising radiation. Studies of volu-
metric changes in the brain have shown greater atrophy in AD subjects,
but also a signiﬁcant overlap with normal aging (Laakso et al., 1995;
Doan et al., 2017; Habes et al., 2016; Pini et al., 2016; Wisse et al.,
2014). Furthermore, atrophy indicates signiﬁcant cell death has already
occurred. For this reason, it is a priority to identify changes that are a
precursor to irreversible atrophy, including those changes that may be
detected by chemical imaging, to enable earlier diagnosis and possible
future protective intervention.
1.2. Brain iron in Alzheimer’s disease
Over a century ago, developments in histological methods allowed
demonstration of iron in mammalian tissues, underpinning the sub-
sequent investigation of iron and other transition metals in the human
brain in health and disease (Perls, 1867). The descriptions of metal
distributions throughout the cellular architecture of the brain are ac-
companied by quantitative post-mortem measurements of metal con-
centrations, such as the study of iron levels in the healthy human brain
as a function of age by Hallgren and Sourander in 1958 (Hallgren and
Sourander, 1958). The concentration and distribution of transition
metals, including iron, are of particular interest in the context of neu-
rodegenerative diseases. In certain rare disorders, iron dysregulation is
a primary cause of mortality (Kumar et al., 2016), but in other neuro-
degenerative disorders the impact of observed iron dysregulation is less
clear. Many studies have shown altered non-haem brain iron in speciﬁc
regions of the AD brain (Samudralwar et al., 1995; Cornett et al., 1998;
Loeﬄer et al., 1995; House et al., 2008; Thompson et al., 1988; Dedman
et al., 1992; Connor et al., 1992; Deibel et al., 1996; Tao et al., 2014;
Pankhurst et al., 2008; House et al., 2007; Akatsu et al., 2012; Graham
et al., 2014; Hare et al., 2016; van Duijn et al., 2017), also in Parkin-
son’s disease (Dexter et al., 1991; Oakley et al., 2007; Wang et al.,
2016) and Wilson’s disease (Dusek et al., 2017) amongst others. Con-
ﬂicting results in the literature may be at least in part due to variability
in sample archiving conditions and analytical methods, but there is
undoubtedly a spectrum of ‘normal’ regional brain iron concentrations
even taking into account variables such as health and age. The disparity
is likely not fully captured in the current literature, given that studies
where no signiﬁcant diﬀerences between populations are observed may
be unpublished or less frequently cited. In an analysis of the literature
only the putamen was found to have signiﬁcantly elevated iron in AD
(Schrag et al., 2011). A subsequent meta-analysis by Tao and co-
workers (Tao et al., 2014) evidenced elevated iron concentration in
eight regions of the AD brain compared with healthy controls, speciﬁ-
cally: frontal lobe, parietal lobe, temporal lobe, amygdala, putamen,
globus pallidus, cingulate cortex, and caudate nucleus.
1.3. MRI evaluation of brain iron in Alzheimer’s disease
Since the contribution of iron to MRI contrast was recognised and
explored in the 1980s (Drayer et al., 1986), a number of diﬀerent
techniques have been developed to calculate tissue iron content in or-
gans, including liver and heart, so that this can be used in the evalua-
tion of patients, especially those with iron-overload disorders (St Pierre
et al., 2004; Wood, 2011). Changes in non-haem iron have the potential
to act as a marker of AD, because of the impact of brain tissue iron on
MRI, aﬀecting tissue susceptibility and relaxation parameters (Haacke
et al., 2005). This has been demonstrated in various systems ranging
from phantoms and animal models (Vymazal et al., 1992; Yang et al.,
2013; Tan et al., 2014; Gossuin et al., 2004) to human post mortem
tissue (House et al., 2008; Langkammer et al., 2010; Bulk et al., 2018;
Antharam et al., 2012; Langkammer et al., 2012).
MR relaxometry techniques allow the quantitative mapping of the
relaxation rates R1, R2, R2*and related parameters (e.g. R2’). As the
transverse relaxation rate R2, and to a lesser extent the longitudinal
relaxation rate R1, have been shown to be linearly proportional to the
iron concentration at ﬁeld strengths up to 7 T (Gossuin et al., 2004), MR
relaxometry can provide a tool for investigating brain iron in vivo
(Langkammer et al., 2014; Ghadery et al., 2015; Tang et al., 2018). A
linear correlation has also been shown between R2* and iron con-
centration at ﬁelds of 1.5 T – 7 T (Yao et al., 2009), with a steeper
gradient (and therefore greater sensitivity) than R2 at 3 T, the ﬁeld
typically used in clinical neuroimaging (Langkammer et al., 2010). As
alternative and more sophisticated MRI measures of iron are developed,
the well-established clinically-accessible R2 and R2* sequences that
have been validated post-mortem retain value for the determination of
iron, and oﬀer potential to detect changes in brain iron distribution and
concentration as a function of AD in critical regions such as the hip-
pocampus and amygdala (Langkammer et al., 2014; Tang et al., 2018).
The ﬁeld dependent R2 increase (FDRI) is the degree to which the
value of R2 depends on the external magnetic ﬁeld. Bartzokis and co-
workers used this property to develop a means of examining iron
content in R2 MRI scans (Bartzokis et al., 1993). R2 was obtained from
dual echo sequences measured at two diﬀerent ﬁeld strengths; the
diﬀerence calculated determined the FDRI. They showed that FDRI of
the frontal white matter, caudate nucleus, putamen, and globus pallidus
correlated strongly with published iron concentration values in healthy
adults and with phantoms of ferritin containing agarose gels (Bartzokis
et al., 1993). FDRI has since been used to study ferritin iron con-
centration in AD compared to control (Bartzokis et al., 1994) and also
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in other neurodegenerative diseases such as Parkinson’s disease and
Huntington’s disease (Bartzokis et al., 2004; Bartzokis and Tishler,
2000). The obvious disadvantage of FDRI is that it requires MRI map-
ping with two diﬀerent instruments, increasing the cost and time of the
imaging. It also requires careful matching of anatomical features across
the two data sets. A recent publication compared FDRI obtained at 1.5 T
and 4.7 T to predicted iron content from a single T2* measurement at
4.7 T and concluded that FDRI oﬀered few advantages over measure-
ments at a single ﬁeld (Uddin et al, 2016). Similarly, in R2 measure-
ments that used four single-echo acquisitions in a study of 10 healthy
adults, we found that the quality of the linear relationship between R2
and predicted iron values was only slightly more robust for FDRI using
3 T and 1.5 T, than for just the R2 data obtained at 3 T (Collingwood
et al., 2014).
Tissue degeneration, which occurs in AD, causes increased water
concentration in the tissue and reduces R2 (Bondareﬀ et al., 1988;
Bartzokis et al., 1994) in opposition to the eﬀect of increased iron
concentration. R2’ is the portion of R2* that is caused by the dephasing
of spins due to inhomogeneity of the local ﬁeld, and is independent of
water concentration (Yablonskiy and Haacke, 1994; Jensen and
Chandra, 2000). Ordidge and co-workers developed a method for
mapping R2’ that reduces the inﬂuence of background ﬁeld variations
and used this technique to measure an increase in iron in the SN of
Parkinson’s disease patients that agrees with post mortem studies, but
that had not been observed in R2 mapping (Ordidge et al., 1994).
Susceptibility weighted imaging (SWI) uses a mask of phase informa-
tion to enhance the contrast in an MR image. The mask can be chosen to
highlight particular phases (features), so that the combined magnitude
and phase information can be used, for example, to enhance contrast
between grey and white matter (Haacke et al., 2004), resolve structures
not observable with T2 or T1 weighted imaging (Manova et al., 2009)
and examine the iron concentration distribution of brain tissue (Yao
et al., 2009). SWI alone does not allow for quantiﬁcation of the mag-
netic susceptibility of the tissue, and suﬀers from blooming artefacts
(Kim et al., 2017), and developments in post-acquisition processing are
enabling quantitative susceptibility mapping (QSM) to become estab-
lished as a method with excellent sensitivity to iron distribution in
tissue in vivo, including for the evaluation of brain iron in AD at
clinically-routine ﬁeld strengths (Langkammer et al., 2012; Kim et al.,
2017).
The past decade has seen a signiﬁcant shift from 1.5 T to 3 T MRI in
clinical neuroimaging, and the ongoing move to higher ﬁeld strengths
brings access to increased tissue iron contrast. Early work in primate
brain at ﬁelds up to 4.7 T suggested that the increased contrast would
reach a threshold where the magnetisation of ferritin-bound iron be-
came saturated (Bizzi et al., 1990). Subsequent studies in post-mortem
human tissue reported a strong linear relationship was sustained be-
tween iron and R2 at 4.7 T (House et al., 2007), and between iron and
R2* at 7 T post-mortem and in-vivo (Yao et al., 2009). More recent post-
mortem human tissue analysis supports the use of QSM and R2* for iron
quantiﬁcation in tissue at 7 T (Hametner et al., 2018; Betts et al., 2016).
We found evidence of a linear dependence of R2 and R2* on nor-
malized iron concentration in post-mortem human hippocampus im-
aged at 14 T (Antharam et al., 2012), using synchrotron XRF (SXRF)
maps to evaluate the relationship between iron distribution and these
MRI parameters. As relative (rather than absolute) iron concentration
was obtained, the magnitude of the ﬁeld-dependent increase in R2 and
R2* could not be tested at 14 T to determine if the eﬀect was saturating.
The present study, utilizing adjacent tissue blocks to calibrate SXRF
iron maps, demonstrates one route to overcome this constraint. In the
following sections, we discuss approaches to validate the relationship
between clinical imaging parameters (typically MRI) and iron content
in tissue.
1.4. Validating iron contrast in MRI data
Reported values for regional brain iron concentrations vary con-
siderably, as evidenced in the landmark review by Haacke and co-
workers (Haacke et al., 2005). This likely reﬂects a combination of
natural heterogeneity in the population, and diﬀerences attributable to
experimental method and study design. The ﬁeld continues to be con-
strained by an absence of iron concentration data from large well-de-
scribed cohorts. When validating MRI methods for sensitivity to iron in
the brain, many studies (Bartzokis et al., 2000; Gelman et al., 1999;
Persson et al., 2015; Liu et al., 2015; Gao et al., 2017; Collingwood
et al., 2014) have used the data published by Hallgren and Sourander in
1958 (Hallgren and Sourander, 1958) as the deﬁnitive source of in-
formation on regional iron concentration as a function of age in the
normal human brain. Comparatively few studies have quantiﬁed iron in
post-mortem tissue to validate directly the relationship with the MRI
parameters. To date, this has been done for R2 and/or R2* in studies
including post-mortem human brain at ﬁelds from<1 T up to 7 T
(Vymazal et al., 1996; House et al., 2008, 2007; Langkammer et al.,
2010; Yao et al., 2009; Hametner et al., 2018; Bulk et al., 2018). These
studies are critical, as they do not rely on the assumption that the
average iron concentration quoted in the literature accurately re-
presents the iron in the individual(s) they are studying. However, post-
mortem sample archiving and processing presents additional chal-
lenges. It is extremely rare to be in a position to work rapidly and safely
with fresh human brain tissue at body temperature, and the majority of
samples are either fresh-frozen and archived at −80 °C or stored in an
appropriately buﬀered solution containing a chemical ﬁxative such as
formalin to prevent tissue deterioration. Both freezing and chemical
ﬁxation impact absolute relaxation parameters in MRI (Vymazal et al.,
1996; Thelwall et al., 2006; Antharam et al., 2012), and a further
complication of chemical ﬁxation is that it can result in unpredictable
levels of mineral transformation and/or metal leaching from the sam-
ples (Gellein et al., 2008; Dobson and Grassi, 1996). Some have sought
to quantify the impact of iron loss in this context: Hametner and co-
workers report 20% loss from in white matter, and 27% loss from pu-
tamen, after 24 days in ﬁxative (Hametner et al., 2018). In the present
study only fresh-frozen tissues were used, by following previously es-
tablished protocols to enable sequential imaging analysis by MRI and
SXRF (Antharam et al., 2012).
1.4.1. Validation by synchrotron X-ray ﬂuorescence mapping
Synchrotron X-ray ﬂuorescence mapping of biological tissues can be
used to produce highly sensitive and speciﬁc maps of elemental dis-
tributions in tissue at high spatial resolution (Collingwood et al., 2005;
Ugarte et al., 2012; Gallagher et al., 2012). The method oﬀers sig-
niﬁcant advantages over histochemical staining with sensitivity to trace
concentrations, speciﬁcity for the chemical elements present (e.g. un-
ambiguous distinction between copper and zinc), and no requirement
for any labelling or contrast agent. Simultaneous acquisition of the
elemental spectra within a pixel, enabling a full analysis of the chemical
elements present within the energy range of the instrument used, can be
performed for a single tissue section (Collingwood and Adams, 2017). A
number of studies have now sought to correlate MRI maps (either
contrast-weighted or parametric) with post-mortem tissue sections
(either chemically-ﬁxed or fresh-frozen) analysed by SXRF, for example
(Hopp et al., 2010; Antharam et al., 2012; House et al., 2014). This has
enabled direct comparison of the spatial distribution of iron with MRI
data. One approach is to use rapid scanning SXRF, where this is cali-
brated with metal foils to compare iron distribution with SWI obtained
at clinical spatial resolutions at 1.5 T, evidencing a linear relationship
between SWI and iron concentration in 1mm thick ﬁxed brain tissue
(McCrea et al., 2008; Hopp et al., 2010). This approach oﬀers the ad-
vantage of being able to cover a spatial area encompassing multiple
regions of the human brain (which is not normally viable with the
micro-focussed SXRF beam). However, it requires chemically ﬁxed
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samples or a cryo-environment that can accommodate large area ras-
tering of a frozen tissue sample, and the calibration with metal foils is
constrained by matrix diﬀerences between the foils and the tissues.
In the present study we incorporate a method previously developed
by our group to obtain MRI and SXRF data from fresh-frozen human
hippocampus at high spatial resolution (60 μm in-plane) at 14 T
(Antharam et al., 2012). Here, equivalent measurements are performed
for a series of brain regions from AD and healthy control cases, with the
MRI analysis performed at 9.4 T. The additional step of calibrating the
iron SXRF signal intensity using high precision bulk analysis of re-
presentative adjacent tissue samples permits determination of the de-
pendence of R2, R2* and R2’ as a function of iron concentration, and to
test the dependence of these relationships at a ﬁeld exceeding 7 T.
2. Materials and methods
2.1. Samples
All tissues used in this study were from donated human brain pro-
vided by the Canadian Brain Tissue Bank and studied under ethical
approval 07/MRE08/12. Tissue samples from two control (males, aged
76 and 78) and three conﬁrmed AD cases (male, aged 73, females, aged
75 and 95) were investigated with samples taken from regions of the
basal ganglia: primarily the caudate nucleus (CN), putamen (Pu),
globus pallidus (GP) and substantia nigra (SN). Based on prior meta-
analyses, the Pu is most likely to show increased iron concentration in
AD. Where additional adjacent structures were included in MRI sam-
ples, such as the anterior limb of the internal capsule which is adjacent
to the caudate nucleus, these have been segmented and included in the
analysis. Case details and the samples measured for each case are given
in Table 1; all samples had been stored at−80 °C. Each SXRF map took
upwards of 6 h to collect, and as synchrotron beam time is limited only
one section was imaged for each region per individual.
The experimental strategy was to cut pairs of blocks (adjacent
tissue) from within each anatomical structure. Examples of the frozen
blocks, prior to dissection, are given in Fig. 1. The ﬁrst block (A) was
used for MRI quantitative relaxometry and SXRF mapping, and was cut
to ﬁt inside a 20mm diameter NMR tube. Dissection included tissue
from surrounding structures to aid anatomical orientation. Block B, for
iron quantiﬁcation in this study by ICP-MS (where GFAAS might be
used as an alternative), was selected to include only the target struc-
ture. The quantitative iron information from block B was used to cali-
brate the iron distribution maps from block A. As the SN anatomy is
diﬃcult to deﬁne with precision in unstained tissue, the cerebral crus
was included in both samples. Where available sample volume or
asymmetry prevented block B from being representative of block A (in
the present study this was the case for the GP samples), the relationship
between absolute iron content and SXRF signal was used to calibrate
the GP images as described in section 3.1.
Before dissection, samples were warmed from archive conditions at
−80 °C to a few degrees below 0 °C. They were then dissected in the
temperature-controlled environment of a cryomicrotome. All sample
handling was performed using acid-washed non-ferrous surfaces and
tools, including ceramic blades for dissection to avoid metal particulate
contamination.
2.2. Bulk iron quantiﬁcation
There are several methods by which the concentration of a chemical
element may be determined with great accuracy. Here we include data
from two example methods that are suitable for iron determination in
brain tissue. The ﬁrst is inductively coupled plasma mass spectrometry
(ICP-MS), here used to determine iron concentration in block B for the
CN and Pu samples, and the second is graphite furnace atomic ab-
sorption spectroscopy (GFAAS) used for the equivalent blocks of SN
tissue. Each method presents its own challenges, and is described in
detail in the supporting references. The SN block B samples were ana-
lysed by GFAAS (instead of ICP-MS) as they were measured in the
context of a study parallel to the main MRI-SXRF investigation (Visanji
et al., 2013; Finnegan, 2013). Ideally the same technique and instru-
ment would have been used to measure all the bulk iron concentrations,
but the sensitivity and accuracy of these methods were suﬃcient (as
discussed in Section 3.3.1 Method Assumptions), that here it was ap-
propriate to pool the data for the purpose of the regression analysis.
2.2.1. Inductively coupled plasma mass spectrometry (ICP-MS)
Iron concentration was determined for the individual tissue blocks
by ICP-MS, using the ICP-MS Agilent technologies 7500 series as pre-
viously described (Finnegan, 2013). Brieﬂy, the samples were freeze
dried and transferred into acid washed 3ml capacity glass Wheaton v-
vials for digestion in 72% double distilled nitric acid. A total of 1.5 ml of
nitric acid was added to the vials in aliquots of 0.5ml and then the
samples were dissolved in a 55 °C oven for approximately 20 h. Each
sample was diluted to 1:100 using Milli-Q® grade water (18.2 MΩ).
Blanks consisting of a 1:100 dilution of the 72% nitric acid used for
digestion were run after every 4 samples and consistently produced an
iron concentration below the detection limit of the spectrometer.
2.2.2. Graphite furnace atomic absorption spectroscopy (GFAAS)
GFAAS was used to measure the iron concentration of the substantia
nigra samples as previously described (Visanji et al., 2013). Brieﬂy, a
Mars Xpress microwave was used to digest the tissue samples in 1ml
HNO3 and 1ml H2O2 using a CEM-provided Tissue Xpress program.
Ultrapure water (3 ml) was added and the digest volume corrected for
venting. The iron concentration was determined from 800-fold dilu-
tions using a hollow-cathode lamp at 30mA and atomic absorption
measured at 248.3 nm.
2.3. MRI relaxometry
MRI was performed using a Bruker micro-imaging MicWB40 probe
and a 400MHz vertical wide bore Bruker spectrometer. Each tissue
sample, initially frozen, was suspended in Fluorinert in a standard glass
NMR tube (Antharam et al., 2012; Finnegan, 2013). Samples were
warmed to and maintained at 2 °C throughout the image acquisition,
and re-frozen directly afterwards.
Before imaging, the probe was tuned and matched to the 1H
channel. TopSpin was used to manually shim the gradients and achieve
a smooth free induction decay (FID) of maximum size, and a symme-
trical, as narrow as possible water peak with a full-width-half-max-
imum (FWHM) of< 60 Hz. The Bruker relaxometry scans from
Paravision 4.0 were used: a multi-spin, multi-echo (MSME) sequence to
map T2 and a multi-gradient echo sequence (MGE) to map T2*. The
number of averages, slice thickness and echo times were optimised to
Table 1
Case details for the samples used in this project. The sex and age of each in-
dividual at death is given. For the control cases the cause of death is stated. For
the Alzheimer’s Disease (AD) cases the Braak stage of the disease pathology is
given (Braak and Braak, 1991). The Case References are not linked with the
original numbers issued by the brain bank, they are the identiﬁers corre-
sponding to the supporting analytical information for this study (Finnegan,
2013).
Case Reference Brain regions Sex Age Pathology
C2 Caudate nucleus
Substantia nigra
M 78 Lung cancer
C3 Putamen
Globus pallidus
M 76 Cardiac infarction
AD1 Caudate nucleus M 73 Braak vi
AD2 Globus pallidus
Substantia nigra
F 75 Braak vi
AD3 Putamen F 98 Braak v
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give a good signal to noise ratio for even the rapid decays shown in
tissue with a high iron content. The scan parameters are summarized in
Table 2. Careful shimming was required to ensure optimum signal from
the region of interest.
Scan geometry and workﬂow was similar to that described pre-
viously (Collingwood et al., 2008; Antharam et al., 2012). Low re-
solution scans were used ﬁrst to measure the majority of the tissue
sample volume. Data from these scans were then used to choose the
part of the tissue to image at high resolution in order to obtain the best
representation of the brain region of interest. Low resolution data were
collected by three sets of scans with interleaving geometry. Two sets of
interleaved high resolution scans were used to map a 7mm thick vo-
lume of tissue.
The decays were ﬁtted to create T2 and T2* maps using the open
source software Image J with the plugins ‘Bruker Opener’ and ‘MRI
Processor’. The MRI Processor plugin was used to ﬁt the T2 and T2*
decays for the voxels in each respective dataset to mono-exponential
Equation 1 using a Levenberg-Marquardt algorithm.
= +
−y A Ce
t
T( )2 (1)
where the constant A takes into account a ﬁnite background. The re-
ciprocal of the T2 and T2*images provided the R2 and R2* images re-
spectively.
2.4. Histology
The tissue blocks that had been initially imaged by MRI microscopy
were subsequently mounted to permit cryosectioning in the same plane
as the virtual slices in the MRI acquisition. Sectioning was performed in
a Leica cryomicrotome (Jung CM3000) at an angle of 10 ° and a nom-
inal thickness of 30 μm. Sections were cut with an acid-washed sapphire
blade to avoid metal particulate contamination from the stainless steel
blades used in routine sectioning. Serial sectioning was performed, with
sections for SXRF analysis mounted on spectroscopically clean quartz
slides, and adjacent sections mounted on glass histology slides and
stained with a standard haematoxylin and Congo red protocol
(Finnegan, 2013). Only haematoxylin staining was used for the quartz
sections after SXRF imaging, and initial ﬁxation required in ice-cold
ethanol (Gallagher et al., 2012), as extended imaging can render the
organic material in the tissue section very fragile. This, combined with
the absence of an adherent coating on the slides (to avoid a potential
source of contamination) resulted in development of a staining protocol
using a liquid blocking PAP pen so that sections could be individually
stained with the slide maintained in a horizontal position (Finnegan,
2013).
2.5. Synchrotron X-ray ﬂuorescence microfocus imaging
SXRF mapping of elemental metal ion distributions was performed
at the microfocus beamline I18 at Diamond Light Source, following
previously described protocols (Antharam et al., 2012; Gallagher et al.,
2012). Brieﬂy, a 10 keV primary beam was used to excite ﬂuorescence
from the unstained tissue section, with the incident ﬂux I0 limited to
avoid saturation of the nine element Ge detector. The quartz-mounted
sections were protected during measurement under an X-ray trans-
parent Kapton ﬁlm, and mounted with the imaging plane at 45° to I0
and the detector at 90° to I0. The quartz has a spatially uniform ﬂuor-
escence signal making it straightforward to subtract it as a contribution
to background noise in the acquired spectrum. It is also very rigid
which is an advantage during SXRF measurement, and tolerates ex-
posure typically required for supporting histological analysis. However,
as it blocks transmission of much of the hard X-ray beam, it is helpful to
use a transparent support ﬁlm for samples where analyte concentrations
approaches the detection limits at the beamline. This permits a pair of
detectors to be positioned, each at 90° to I0, to maximise the solid angle
over which ﬂuorescence from the sample is acquired (Mosselmans
et al., 2009; Collingwood and Adams, 2017).
To enable correlation with the MRI R2 and R2* maps, tissue sections
corresponding to the higher resolution MRI images were mapped over
the full slice area of interest, and the adjacent (glass-mounted) section
which had been histochemically stained was used to conﬁrm the area
required. Rastering in the focused X-ray beam provided in-plane
60× 60 μm pixels where the X-ray beam sampled the full depth of the
tissue section; the acquisition rate corresponded to a 1 s dwell per point
in the image matrix. A full SXRF spectrum was acquired for each pixel,
and these spectra were processed using the open source software
PyMCA (Solé et al., 2007), which was used to ﬁt all detectable elements
within the accessible energy range and compute the signal intensity
from the primary ﬂuorescence peak for each element. The spectrum in
each pixel was normalised to the corresponding I0 value to remove the
eﬀect of changing incident ﬂux over the period of measurement, and
the signal from a blank area on each quartz slide was used to correct for
any diﬀerence in sample-detector distance. The resulting spectra were
processed to produce precise maps of the normalized concentration
distribution of the primary transition metals present in each tissue
section (Finnegan, 2013).
2.6. Correlating SXRF and MRI images
The SXRF iron maps acquired from the 30 μm thick sections were
correlated with the MRI microscopy data obtained with slightly lower
(86×86 μm) in-plane spatial resolution and 150 μm thick virtual
slices. By taking thinner sections for SXRF, this ensured that several
serial cryosections could be well-matched to each virtual MRI slice.
Image J was used to rotate the images from the diﬀerent modalities to
achieve a common orientation, and this was achieved by comparing
Fig. 1. Examples of the tissue blocks from the Canadian Brain Tissue Bank prior
to dissection for imaging and bulk analysis, with anatomical orientations in-
dicated (A/P: anterior/posterior; L/M: lateral/medial; S/I: superior/inferior).
Table 2
Scan parameters for MRI relaxometry at 9.4 T for the low-spatial-resolution and
high-spatial-resolution imaging of the tissue blocks. MSME=multi-slice multi-
echo; MGE=multi-gradient-echo. TR = repetition time. TE = echo spacing.
Measurement: T2
(low res)
T2
(high res)
T2*
(low res)
T2*
(high res)Parameter:
Resolution (μm) 195×195 86×86 195×195 86×86
Slice thickness (μm) 250 150 250 150
Scan sequence MSME MSME MGE MGE
Attenuators: A0, A1 16, 3 16, 3 22.5, - 22.5, -
TR (ms) 7000 7000 3500 4000
TE [T ﬁrst echo] (ms) 7.248 9.783 6.0 [3.08] 6.0 [3.90]
No. of echoes 16 16 16 16
No. of averages 2 4 2 4
Scan time 22m24s 1h29m36s 11m12s 51m12s
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anatomical features in the SXRF and MRI images, and microscope
camera images of the stained and unstained SXRF section and the ad-
jacent histochemically stained tissue sections. Factors that occasionally
compromised correlation of the images included any misalignment of
the block for sectioning, slight deformation of the tissue by the
Fluorinert during MRI analysis, or sectioning artefacts such as cracks or
folds in the unembedded tissue. This approach, in combination with the
careful preservation of tissue architecture, made manual correlation
viable at the level of individual brain regions.
2.7. Statistical analysis
SSPS Statistics Version 21 was used to carry out linear regression
analysis, creating simple linear regression models to describe the re-
lationship between the measured MRI parameters (dependent variables:
R2, R2*, R2’) and the predictor (independent variable: iron). The cor-
relation coeﬃcient, r, described the linear relationship, and the good-
ness of ﬁt was reported as r-squared. SSPS was used to calculate a p-
value for the predictor in each case, testing for violation of the null
hypothesis, that there was no dependence of each measured MRI
parameter (R2, R2*, R2’) on iron, at a signiﬁcance level of p < 0.05.
3. Results and discussion
Examples of matched SXRF and R2 images, showing the approx-
imate boundaries for segmentation, are given in Fig. 2, and the struc-
tures segmented for analysis are detailed in Table 3; those structures
adjacent to the main regions of interest were segmented where possible.
The correspondence between the SXRF and MRI images permitted de-
termination of the relationship between the MR relaxation values and
the associated iron concentration in each region. One section included
elevated iron directly associated with a major blood vessel; the aﬀected
region was excluded from the analysis.
3.1. Calibration of SXRF maps
The iron concentration represented by one unit of normalised SXRF
signal intensity was calculated for each sample by dividing the mean
SXRF signal for that region by the mean bulk iron concentration mea-
sured in the adjacent tissue block. The mean and standard deviation for
each sample was calculated and then averaged for all samples giving a
mean of 7.3 ± 12% μg Fe / g hydrated tissue for every unit of nor-
malised SXRF intensity.
3.2. The dependence of R2, R2*, and R2’ on iron concentration
Fig. 3 shows the mean iron concentration versus R2 and R2* for each
of the main segmented regions from the correlated SXRF and MRI
image data, for the pooled data, and separately for the grey matter
(GM) and white matter (WM). The prediction bands show the range
within which 95% of any new measurements would be expected to fall.
The linear regression analysis described in Fig. 3, and the results of
this analysis set out in Table 4, produced the following equations re-
lating R2 and R2* (s−1) to iron concentration ([Fe] in μg/g, with an
Fig. 2. Matched and segmented SXRF transition metal maps and MRI R2 and R2* maps from a) the substantia nigra and b) the globus pallidus regions in case AD2.
During segmentation the intensity maps for the high abundance elements as well as the individual transition metals, were used to aid boundary identiﬁcation. Here,
RBG images are shown to illustrate how there are distinct distributions of Fe, Zn, and Cu at this level of structural organisation. In the multi-metal maps these are
represented as Fe (red), Cu (green), Zn (blue). The accompanying scale bars show the computed R2 and R2* values for the MRI maps, and the temperature scale bars
for the transition metal maps show the normalized ﬂuorescence intensity. Labels for the segmented regions are deﬁned in Table 3.
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estimated experimental uncertainty of± 12%:
= +R 0.072 [Fe] 202 (2)
= +R 0.34 [Fe] 372* (3)
The linear relationship proved robust, regardless of whether the
data were grouped by disease, or tissue type (grey or white matter).
Furthermore, the slope and intercept of the ﬁtted lines agree within
error for each model for both R2 and R2*. In a prior study of the hip-
pocampus (Antharam et al., 2012), we previously demonstrated that
areas of increased iron concentration corresponded to increased R2 and
R2* in matched MRI and SXRF maps at 14.1 T, but here the relationship
was not quantiﬁed. Although a strong linear relationship has previously
been shown between iron and R2* at lower ﬁelds (between 1.5 T and
7 T (Yao et al., 2009)), this present study provides, to the best of our
knowledge, the ﬁrst demonstration of the linear relationship between
iron concentration and R2 and R2* in human brain tissue at 9.4 T and
the ﬁrst demonstration, with quantiﬁed iron values, above 7 T.
In clinical MRI imaging the diﬀerent relaxation rates of grey and
white matter tissues provide contrast in the image and this is attributed
to their diﬀering fat and water content in addition to iron content.
However, in this study the agreement of the linear relationship between
iron and R2 and R2* for both grey and white matter suggests that at
9.4 T, iron is the most signiﬁcant factor in determining the value of R2
and R2*. The r-squared values obtained in the regression analysis in-
dicate that> 65% of variation in the data is accounted for by this linear
relationship. The evidence for this has not always previously been ap-
parent in studies including white matter (House et al., 2008), and here
the inclusion of white matter regions with higher iron levels than ty-
pically observed in cortical regions may be a factor. The linear re-
lationship we report at 9.4 T is not observed below a threshold of
100 μg/g, and this observation is in keeping with prior work at 4.7 T
reporting a threshold of 55 μg/g for R2 (House et al., 2007). We con-
sider the relationship between R2, iron, and ﬁeld strength in the fol-
lowing section.
The eﬀect of iron on R2 increases linearly with ﬁeld strength (B,
Tesla), as formerly described empirically by Vymazal and co-workers
(Eq. (4)). They derived this from iron and R2 data measured at multiple
ﬁeld strengths (0.05 to 1.5 T) at 37 °C in primate brain tissue (Vymazal
et al., 1996).
= +
−slope 14.1 6.2B s /mg/g1 (4)
When Eq. (4) is solved for an imaging ﬁeld of 9.4 T (400MHz), it
gives a slope of 0.0724 s−1/μg/g. This compares extremely well with
the gradient of Eq. (2) above, 0.072 ± 0.008 s−1/μg/g, with no evi-
dence of saturation of the ﬁeld dependent R2 increase at 9.4 T.
House and co-workers also compared their observations at 4.7 T to
Vymazal’s prediction and noted good agreement after accounting for
diﬀerences in experiment design (House et al., 2007). Therefore, while
the agreement we observe between our ﬁndings for R2 and Vymazal’s
prediction is excellent, it is important to note diﬀerences in experiment
design that may contribute experimental uncertainty in addition
to± 12% arising from calibration of the iron images with the SXRF
data:
1 R2 may be increased in tissue which has been frozen and defrosted
(Vymazal et al., 1996), and the samples used to determine Eq. (4)
were fresh compared with the defrosted post-mortem human brain
used in the present study.
2 R2 has been shown to decrease with temperature (Kamman et al.,
1988) and Eq. (4) is for tissue at 37 °C compared for the present
study performed at 2 °C.
3 The inter-echo time used in the sequence to obtain R2 may inﬂuence
the eﬀect of iron content on R2 (Vymazal et al., 1996).
The susceptibility related relaxation rate R2* is generally under-
stood to represent the combination of the transverse relaxation rate R2
and the ﬁeld inhomogeneity induced R2’. R2* is reportedly more sen-
sitive to changes in tissue iron concentration than R2 (Langkammer
et al., 2010), and this is reﬂected in the present results (Fig. 3, Eq. (3)).
The approximate mean R2’ was subsequently calculated for each seg-
mented region, using Eq. (5):
= −R ' R R2 2* 2 (5)
and plotted against iron concentration as shown in Fig. 4 with the re-
sults of linear regression analysis for the combined and separated
control and AD data, conﬁrming a strong linear dependence of R2’,
consistent with the earlier results for R2 and R2*. We note that the
gradient for this relationship for R2’ is 3.75 times larger than the gra-
dient for R2 (Fig. 3, Eq. (2)). These gradients have been reported ap-
proximately equivalent at 3 T (Gelman et al., 1999), so these new data
at 9.4 T indicate that not only is there a B-ﬁeld-dependent contribution
to the relationship between of R2 with iron (Vymazal et al., 1996); there
is also a ﬁeld-dependent contribution arising from the dependence of
R2’ on iron concentration. It is reasonable to assume a linear relation-
ship between the magnitude of the ﬁeld B and R2’, as this has previously
been shown for the ﬁeld-dependence of R2* (Yao et al., 2009). The
present result obtained at 9.4 T and the prior result from Gelman and
co-workers at 3 T can then be used to compute the gradient (slope) for
the dependence of R2’ on iron concentration at a particular imaging
ﬁeld B as follows:
= − +
−slope 51.1 34.4B s /mg/g1 (6)
It is long-postulated that MRI-detectable changes in iron con-
centration may aid diagnosis of neurodegenerative disorders, including
AD (Antharam et al., 2012; Haacke et al., 2005; Langkammer et al.,
2014; Bartzokis et al., 1994). In the present study, despite the strong
linear relationships established with a very small sample size, the
Table 3
Summary of the regions segmented in the SXRF and MRI R2 maps.
Region Main Structures Additional Structures
Caudate Nucleus caudate nucleus (CN);
anterior limb of the internal capsule (AIC-CN);
white matter medial to the caudate nucleus (WM-CN)
n/a
Putamen putamen with high iron concentration (Pu_high);
putamen with low iron concentration (Pu_low);
white matter lateral to the putamen (Pu-WM)
Control sample only: anterior limb of the internal capsule (AIC-Pu)
Globus Pallidus external globus pallidus (GPe);
putamen with high iron concentration (Pu_high-GP);
lamina of white matter separating the external globus pallidus and putamen (WM-
GP)
Control sample only: internal capsule (IC); internal globus pallidus
(GPi)
AD sample only: putamen with low iron concentration (Pu_low-GP)
Substantia Nigra substantia nigra (SN);
cerebral crus (CC)
n/a
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indications are that a substantial increase in tissue iron would be re-
quired to be reliably detected as a deviation from normal levels ob-
served in cross-sectional studies, even at the highest clinically-available
ﬁelds. The evaluation of multiple regions, and of more than one marker
of iron status, oﬀers scope to discriminate between disease states even
in small cohorts (Visanji et al., 2013). Given the heterogeneity in
normal regional iron concentration, it is likely that longitudinal ima-
ging to track change in individuals may provide the greatest sensitivity
and speciﬁcity to detect changes in the chemistry of the brain.
3.3. Method assumptions
3.3.1. ICP-MS and GFAAS determination of iron concentration are
equivalent
As noted in Section 2.2, practical constraints in the present study
resulted in most of the bulk analyses being performed using ICP-MS,
Fig. 3. Iron concentration versus R2 and R2* at 9.4 T. Results from linear regression analysis are shown in graphs a) and b) for the dependence of R2 and R2*
respectively on iron concentration in the pooled control and AD data. The light grey error bars represent the standard deviation within each the segmented region,
and are primarily a measure of signal heterogeneity rather than experimental uncertainty. The upper x-axis shows normalised SXRF iron signal intensity and the
lower x-axis shows the calibrated iron concentration. The prediction bands show the region in which 95% of any new measurements would be predicted to fall.
Graphs c) and d) show the dependence of R2 and R2* respectively on iron for control GM (ﬁlled symbol) and WM (open symbol) samples; e) and f) show the
equivalent data from the AD cases. The results support a linear relationship, with r> 0.85 in all examples.
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with the exception of the SN blocks which were analysed by GFAAS. In
order for the equivalence of these measures to be a justiﬁed assumption,
careful calibration and quantiﬁcation were performed for both methods
(Finnegan, 2013; Visanji et al., 2013). In each case, signal is obtained
from the analyte following dissolution of the complete tissue block,
rather than selectively sampling within a volume of interest, and there
is no reason to expect any deviation in accuracy given that both pro-
cesses included careful calibration. An extensive review of post-mortem
iron quantiﬁcation by Haacke and colleagues (Haacke et al., 2005),
which is summarized in Table 3.2 in (Finnegan, 2013), includes re-
ported values for these same regions of the brain obtained by both ICP-
MS and atomic absorption spectroscopy (AAS). There is no systematic
diﬀerence in the reported values as a function of analytical technique:
in some cases AAS returns higher concentrations, in other cases ICP-MS
is higher. We suggest that the greatest source of experimental un-
certainty will be in the method of dissection, and that having a single
team perform all the dissections in a consistent manner (as was the case
for the present study) is a critical factor in minimising experimental
uncertainty.
3.3.2. Adjacent tissue blocks for bulk and SXRF analysis have equivalent
iron concentrations
The method of calibrating the SXRF maps assumes that the tissue
samples measured with ICP-MS or GFAAS and the corresponding ROIs
mapped by SXRF have an equal concentration of iron. The dissection of
each block was carefully planned in order to best achieve this, for ex-
ample, the substantia nigra shown in Fig. 1 (AD2) was bisected parallel
to the plane of the image to obtain SNpc and SNpr in both blocks. Tissue
samples were approximately 1 cm thick, with the centre of adjacent
samples (for bulk iron concentration and SXRF) approximately
0.5–1 cm apart. The validity of the assumption of equivalent iron con-
centrations was tested for relative levels, not absolute concentrations,
by calculating the ratio of AD to control iron concentration for the bulk
tissue iron measurements and the mean relative iron concentration
measured by SXRF mapping. The ratios were in good agreement [CN:
bulk tissue iron 3.04 versus SXRF 2.80 (8% diﬀerence); Pu: bulk tissue
iron 1.28 versus SXRF 1.24 (3% diﬀerence); SN: bulk tissue 1.50 versus
SXRF 1.41 (6% diﬀerence)]. Agreement of these ratios within 10% in-
dicates that the relative iron concentrations are well-preserved across
the tissue volumes sampled.
Table 4
Results of linear regression analysis of iron versus R2 or R2*. a) The linear relationship between iron and R2. b) The linear relationship between iron and R2*. The
relationship is examined for the control and AD data separately and with both sets of data pooled. Data from grey and white matter regions is also examined
separately. In all cases there a statistically signiﬁcant, strong linear relationship. The r-squared values show that at least 67% of the variation in the data is explained
by the linear relationship. All R2 models show a slope and intercept which agree within error. The same is true for all of the ﬁts to the R2* data. *p < 0.05;
**p < 0.01; ***p < 0.001.
a) Iron vs. R2
Tissue regions Disease n Slope
(s−1/(μg/g))
Intercept (s-1) r r2 p
All pooled 22 0.072± 0.008 19±2 0.87 0.75 ***
Control 11 0.072± 0.009 21±2 0.93 0.87 ***
AD 11 0.079± 0.012 17±4 0.88 0.77 ***
GM Control 6 0.072± 0.011 19±2 0.96 0.92 **
AD 6 0.076± 0.027 16±8 0.82 0.67 *
WM Control 5 0.076± 0.013 22±3 0.96 0.91 *
AD 5 0.094± 0.016 18±3 0.96 0.92 **
b) Iron vs. R2*
Tissue regions Disease n Slope
(s−1/(μg/g))
Intercept (s-1) r r2 p
All pooled 22 0.34± 0.04 37±9 0.87 0.75 ***
Control 11 0.35± 0.05 38±10 0.93 0.87 ***
AD 11 0.35± 0.07 30±17 0.87 0.75 ***
GM Control 6 0.35± 0.10 35±21 0.87 0.76 *
AD 6 0.35± 0.12 16±35 0.82 0.7 *
WM Control 5 0.36± 0.06 41±120 0.97 0.93 **
AD 5 0.42± 0.07 33±150 0.96 0.92 **
Fig. 4. Iron concentration versus approximate R2’. The x-axis at the top of the
graphs shows the normalised iron SXRF signal intensity and the lower axis
shows the calibrated iron concentration. Simple linear regression analysis
shows a strong (r > 0.85) linear relationship between iron concentration and
R2’. The prediction bands show where 95% of any new measurements are
predicted to fall. The slope and the intercept of the ﬁt agree within error for
both the pooled and separated control and AD data, representing 22 samples
from two control and three Alzheimer’s disease cases, encompassing the regions
detailed in Table 3. **p < 0.01; ***p < 0.001.
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3.3.3. SXRF and MRI slices can be correlated despite diﬀerent thicknesses
The diﬀerence in SXRF (30 μm) and MRI (150 μm) slice thicknesses,
despite similar in-plane resolution, means that the SXRF maps account
for iron signal from approximately 20% of the corresponding MRI slice
volume. The properties of the tissue precluded cutting signiﬁcantly
thicker sections for SXRF, and the signal recovery in the MRI would
have been compromised if thinner slices had been obtained. Cutting up
to ﬁve sections for SXRF from within each MRI slice accommodated
minor misalignment of the tissue block, and provided one or more
adjacent sections for staining to conﬁrm tissue architecture. Although
this means the matching between the SXRF and MRI is imperfect, the
method did allow examination of the relationship between iron, R2 and
R2* in unﬁxed samples at higher spatial resolution than in most prior
work, with the anatomical structures of interest substantially unaltered
over the 150 μm length-scale. The spatial resolution made it viable to
explore contrast variation within anatomically deﬁned regions, redu-
cing the need to attempt bulk dissection within subﬁelds. Indeed the
diﬃculty in precisely excising brain structures has been commented on
in the literature (House et al., 2007). The scope for pixel-by-pixel cor-
relation in the ROIs was explored for these datasets, incorporating a
protocol to rescale the MRI data relative to the SXRF data to bring them
into a shared matrix using Matlab. In practice this approach did not
provide such a robust outcome as the method applied in the current
study, which takes the average signal intensity value from segmented
ROIs where each sampled area includes thousands of pixels. This ap-
proach is more robust and pragmatic in studies where sections are
imperfectly matched, as it is less prone to distortions arising from the
experimental uncertainties.
3.3.4. Approaches to quantifying tissue iron distribution
Evaluation of total iron concentration in adjacent tissue blocks was
used here as a pragmatic method to estimate brain iron concentration
distribution in the SXRF iron maps. This was successful, with an ex-
perimental uncertainty± 12% that is equivalent to or is better than the
accuracy typically achieved with SXRF reference foils for tissue samples
due to issues with matrix matching (Collingwood and Davidson, 2014).
It is technically possible to achieve fully quantitative SXRF mapping of
elemental distributions where the phase contrast information can be
measured to perform the necessary mass correction (Kosior et al.,
2012), but this is not yet routinely available at SXRF beamlines. The
rationale for using SXRF here is that it is non-destructive, has a sensi-
tivity that increases with spatial resolution as it is a ﬂux- (rather than
mass-) limited technique, and permits simultaneous acquisition of a rich
multi-element spectral image (Collingwood and Adams, 2017). There
are several excellent alternative beam methods (which by contrast to
SXRF are destructive), including laser ablation ICP-MS imaging and
others reviewed elsewhere (Collingwood and Adams, 2017); for these
alternatives the concentration detection limit decreases as the spatial
resolution of the imaging is increased.
We observed distinct variations in iron distribution both between
and within the primary regions studied. This marked heterogeneity of
iron distribution within the sub-ﬁelds of the brain may in part account
for wide variations in the experimental reports of healthy adult brain
levels (Haacke et al., 2005), along with variations due to the analytical
approach used.
In the study from Frisoni and co-workers: ‘Imaging markers for
Alzheimer disease: Which vs how’, a large number of candidate imaging
markers for AD were evaluated, including volumetric MRI. They con-
cluded that the way in which an imaging marker is measured is at least
as important to its success as the marker itself (Frisoni et al., 2013). This
would certainly apply to the measurement of tissue iron concentration
by MRI.
4. Conclusion
A linear dependence of R2, R2* and R2’ on iron concentration was
observed at 9.4 T, independent of disease state or tissue type. The
gradient of the relationship between iron and R2 agrees with the pre-
dicted relationship at 9.4 T, with no indication of saturation of the ﬁeld
dependent R2 increase. Iron is the focus of the present study as it oﬀers
strong scope for clinical evaluation, but the approach may be used more
widely to evaluate other elements in Alzheimer’s and related disorders,
and to test their relative impact on candidate imaging parameters in-
cluding quantitative susceptibility mapping and other clinically ap-
plicable modalities.
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